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Abstract
Background Based on data of clinical trials, new agents
are receiving approval to the pharmaceutical market, for
which information concerning safety issues under real-life
conditions is not yet available.
Objectives The aim was to evaluate the tolerability of
newer antiepileptic drugs (AEDs), such as topiramate,
levetiracetam, zonisamide, pregabalin, extended-release
oxcarbazepine, lacosamide and eslicarbazepine, under real-
life conditions by means of an assessment of routine clin-
ical data of inpatients.
Method Over 2.75 years data of all inpatients receiving
one of the newer AEDs were documented. Occurring
adverse drug reactions (ADRs) were classified according to
the WHO-UMC Causality Assessment concerning their
likely relationship to the prescribed AEDs. For each AED,
the total number of patients without and with ADRs,
assessed as at least possibly related to the particular drug,
was calculated and corresponding incidences compared
with reference data provided in the Summary of Product
Characteristics (SmPC). For statistical evaluation Spear-
man correlation (rs), estimated relative risk and logistic
regression analysis were used.
Results In total, the data of 562 patients were assessed, of
which 90 % received up to six different AEDs. The pro-
portion of off-label use with regard to dosage varied
between 6.4 and 64.7 %. Levetiracetam and oxcarbazepine
as an extended-release formulation were most commonly
used, and levetiracetam showed the best tolerance. By
using logistic regression, the occurrence of ADRs was
significantly associated with the number of AEDs
(p\ 0.001) as well as the defined daily doses (p = 0.003).
In total, ADRs of AEDs were documented for 318 patients
(56.6 %). The most common referred to electrolyte
imbalance, e.g., low sodium (n = 79, 14.1 %) and potas-
sium (n = 25, 4.4 %) levels, the central nervous system,
including dizziness (n = 61, 10.9 %), disturbed vision
(n = 47, 8.4 %), fatigue (n = 40, 7.1 %), nystagmus
(n = 36, 6.4 %) and ataxia (n = 29, 5.2 %), or cognitive
deficits, especially disturbance of speech (n = 37, 6.6 %),
memory impairment (n = 36, 6.4 %) and mental slowing
(n = 32, 5.7 %). By comparing the assessed ADR inci-
dences with specification data, for some ADRs, a probable
underestimation by the SmPC of respective risk could be
assumed.
Conclusion During inpatient treatment, valuable data are
generated, which are currently rarely utilized for pharma-
coepidemiologic or pharmacovigilance purposes. A sys-
tematic evaluation of these data can increase the
probability of detecting ADRs and can promote real-life–
related drug surveillance.
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Key Points
Summary of Product Characteristics data may
underestimate the risk of adverse drug reactions.
Continuous tolerability and safety surveillance is
necessary to align approval data with real-life
experience.
Frequent risk evaluation of drugs by means of
routine clinical data could provide a new quality of
drug surveillance.
1 Introduction
Based on submitted quality, efficacy and safety data, doz-
ens of new agents are receiving approval to the pharma-
ceutical market every year. Despite their promising
advantage to medical care, at the time of approval, there
can be no certainty that these drugs are completely safe [1].
Information about specific population groups can fre-
quently be assumed to be missing as well as data about rare
adverse drug reactions (ADRs) or drug interactions. It is
therefore necessary to establish methods of large-scale
post-marketing surveillance to gather real-life data espe-
cially with regard to safety issues. In most countries a
spontaneous reporting system (SRS) for collecting data of
suspected ADRs is used. Reported data are assessed by the
responsible authority in a global database, which thus
contains a vast data pool of ADRs relating to a wide range
of drugs, in support of its main objective of generating
signals of unknown, rare or serious ADRs [2–4]. This is a
very cost-effective method. However, this kind of drug
safety monitoring also has many limitations, the most
frequently mentioned being the subject of underreporting.
The mentioned reasons for this are manifold, including lack
of time, large effort, fear of being prosecuted, unawareness
of the requirement to report or the estimation that a par-
ticular ADR is not worth noting [3–5]. Also, SRSs are often
believed to be exclusively designed for detecting rare and
serious ADRs, but for general drug safety, the monitoring
of all undesirable reactions is necessary [4]. For the most
accurate relative risk (RR) assessment, exact data of
application or drug utilization is required, which, however,
is only available by approximation. Thus, an SRS has not
got the impact to determine the prevalence rate of a specific
ADR reliably and bears a risk of delay in signal detection.
In the case of diseases requiring lifelong treatment, more
detailed knowledge about the efficacy and tolerability of a
drug, attention to ADRs as well as awareness of patients’
needs are necessary to achieve the best therapeutic out-
come. For epilepsy, as one of these diseases, the occurrence
of ADRs has been shown to have an important influence on
patients’ quality of life [6–9]. Approximately 20 % of all
patients with epilepsy, in the case of refractory epilepsy,
even about 50 %, are on polytherapy, bearing an increased
risk for ADRs and drug interactions [10–13]. Many of
these patients have tried most of the available drugs and are
therefore a target group for new treatment options aimed at
reducing seizure frequency while maintaining or even
optimizing tolerability. Especially in patients suffering
from seizure recurrence, optimizing therapy can be a bal-
ancing act between increasing the drug dosage to maximize
the therapeutic effect and running the risk of ADRs [14,
15]. Over the past 25 years, more than 15 new antiepileptic
drugs (AEDs) with modified acting mechanisms and/or
side effect profiles have become available for epilepsy
treatment, resulting in a major challenge for health pro-
fessionals and post-marketing surveillance in respect of
specified knowledge about tolerability and drug interaction.
Such a level of competence can hardly be generated by
relying only upon a tool like an SRS for monitoring drug
safety. In fact, long-term supervision of medicated patients,
increased sensitivity towards recognizing accumulation of
specific ADRs and deriving remedial measures from these
observations are recommended as vital for a comprehen-
sive risk–benefit evaluation [14]. Accordingly, the sys-
tematic assessment and evaluation of routine inpatient data
was assumed to be one way of obtaining this relevant
knowledge and was therefore investigated in this survey.
2 Methods
2.1 Data Collection
Between May 2008 and December 2010, an in-house
pharmacist attended the Consultants’ ward round once a
week on four different wards of the Bethel Epilepsy Centre,
Bielefeld, Germany, a tertiary reference center for epi-
lepsy. All information taken as part of clinical routine
during the ward round was documented in the patients’
chart as usual and, for later digitalization, concurrently
transcribed to an adjusted record form by the pharmacist.
For every patient a new record form was used for each
week. All inpatients receiving one of the newer AEDs, i.e.,
topiramate (TPM), levetiracetam (LEV), zonisamide
(ZNS), pregabalin (PGB), extended-release oxcarbazepine
[OXC(ER)], lacosamide (LCM) and eslicarbazepine (ESL),
were included. Documented data comprised the specific
drug, all AEDs in use, corresponding daily dosages and
serum levels, if available, age, gender, concomitant
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medication, patient and actual case number. In addition, all
patient-reported and medically diagnosed ADRs were
documented in an unstructured format, and for each one,
the current causality concerning the administered AEDs
was assessed by interprofessional exchange (i.e., physician,
pharmacist, nursing staff). To this end, the temporal pattern
of association between its occurrence and change of med-
ication and all available information concerning concomi-
tant disorders, diseases or medication were taken into
account. For the classification of causality, the WHO-UMC
Causality Categories were used (see the electronic sup-
plementary material, Online Resource 1) [16]. Any severe
or unknown suspected ADRs were immediately reported
via the SRS to the responsible regulatory authority.
2.2 Data Entry
All relevant data were recorded by the pharmacist in an
internal database, using IBM SPSS for Windows 20.0.
Patient data were documented by assigning an individual
patient number, case number, gender, age and date of
observation. In order to enable the evaluation, the initially
documented ADRs were coded numerically according to
the system organ classes (SOCs) of the MedDRA (Medical
Dictionary for Regulatory Activities) terminology, and the
specific symptom. Also, corresponding causality categories
were entered numerically. For every documented ADR and
week, a single data set containing patient details, medica-
tion, daily dosage and causality category for every given
AED was generated. Where the same ADR was docu-
mented more than once for one patient, the first docu-
mented observation and accordingly the one with the
lowest AED dosages was included for analysis only. For
patients without ADRs, the highest AED dosage was
considered. To rule out possible input errors, the data were
entered twice at different times. Asserted discrepancies
were clarified by re-checking the record forms.
2.3 Data Evaluation
Demographic and clinical characteristics of the patients
were evaluated by using the first documented contact after
hospitalization. For every newer AED, the total number of
patients without and with ADRs, assessed with at least
possible causality, and the corresponding dosages were
calculated. Additionally, the same analysis was performed
including only data sets of patients being treated off-label
with regard to the maximum recommended daily dosage in
the Summary of Product Characteristics (SmPC). In both
analyses, every patient was included only once. Further-
more, for every AED, the incidence of the respective ADR
was determined with reference to the number of patients
experiencing this ADR while taking the particular AED
divided by the total number of patients where this AED
was part of the therapy. All estimated incidence rates were
compared with the respective data provided in the SmPC of
each AED [17–23]. The correlation between the number of
AEDs and the total drug load, calculated as sum of the
defined daily doses (DDDs), was determined by Spearman
correlation. For assessing the impact of number of AEDs
and sum of DDDs on the occurrence of ADR, logistic
regression was used.
Concerning tolerability of each AED, the RR of ADR
occurrence was calculated. For this purpose, the data of
LEV were used as the reference, as being the most fre-
quently applied AED in this survey, the first recommended
for treatment of focal epilepsy out of this selection and also
proven as well tolerated [24–28].
3 Results
In total, data of 562 cases were assessed, which equals
around one quarter of the total number of in-house
patients on the attended wards in the same time period.
The corresponding patients’ characteristics, length of stay
and number of AEDs in concomitant usage [mean, median
and standard deviation (SD)] are summarized in Table 1.
For further specification of the antiepileptic therapy, the
number and percentage distribution of patients receiving
antiepileptic monotherapy versus polytherapy of up to six
different AEDs were evaluated on the basis of each ini-
tially documented observation per patient. Hence, 57
patients (10.1 %) were on monotherapy, 192 patients
(34.2 %) were treated with two different AEDs, 205
patients (36.5 %) with three, 88 (15.7 %) with four, 19
(3.4 %) with five and just one patient (0.2 %) with six.
The number of AEDs correlated significantly with the
total drug load as sum of DDDs (rs = 0.661, p\ 0.001).
The mean drug load (± SD) per patient increased with an
increasing number of AEDs from 1.15 ± 0.60 in patients
on monotherapy to 2.42 ± 0.98 in patients on two con-
comitant AEDs, 3.33 ± 1.33 in those on three,
4.50 ± 1.35 in those on four and 5.56 ± 1.28 in those on
five or six.
In monotherapy, as well as in a combination of two
different AEDs, OXC(ER) and LEV were the ones most
commonly used. This is the case for more than 40 % of the
patients. For further information concerning the percentage
of each AED in antiepileptic polytherapy see Fig. 1. LEV
and OXC(ER) were further the most frequently used at all,
with applications documented for 367 and 183 patients,
respectively. For TPM and LCM, the data of 109 and 102
patients were assessed, whereas ZNS (68 patients), PGB
(61 patients) and ESL (17 patients) were a less frequently
used component of the antiepileptic therapy.
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In total, ADRs of AEDs were documented for 318
patients (56.6 %). Logistic regression indicated that the
occurrence of ADRs was significantly associated with the
number of AEDs in polytherapy regime (p\ 0.001) as
well as the total drug load as sum of DDDs (p = 0.003),
whereas each predictor was analyzed separately.
For each of the focused AEDs, the number of cases
without and with an ADR of at least possible causality and
corresponding dosages are listed in Table 2. For none of
these AEDs the sum of percentage of cases without and
with possibly related ADRs achieved 100 %. The differ-
ences, ranging from 4 to 15 %, represent ADRs assessed as
Table 1 Patients’
characteristicsa of 562 in-house
patients treated at the tertiary
reference center for epilepsy
who were receiving at least one
of the newer AEDs







Focal ? generalized 24 4.3
Non-epileptic disorderb 9 1.6
Age (years) 562 37.2 36.0 14.6 16.0 89.0
Length of stay (days) 562 60.6 51.0 38.7 6.0 238.0
No. of AEDs per patient 562 2.64 3.00 1.00 1.00 6.00
Drug load of AEDs (DDD)c 562 3.14 3.02 1.53 0.25 10.82
AED antiepileptic drug, DDD defined daily dose, SD standard deviation
a Calculated by including every first documented observation of each patient
b Differential diagnosis of a paroxysmal non-epileptic disorder obtained during hospitalization

















































Fig. 1 Percentage of patients treated with the respective AED,
stratified by monotherapy and the different kinds of polytherapy (left
to right). Total percentage of patients taking respective drug either as
monotherapy or part of polytherapy: LEV 66.19 %, OXC(ER)
32.38 %, TPM 19.4 %, LCM 18.15 %, ZNS 12.1 %, PGB 10.68 %,
and ESL 3.02 %. AED antiepileptic drug, ESL eslicarbazepine, LCM
lacosamide, LEV levetiracetam, OXC(ER) oxcarbazepine extended-
release formulation, PGB pregabalin, TPM topiramate, ZNS
zonisamide
212 A. Hilgers, M. Schaefer
unlikely, conditional or not causally linked to the particular
AED. In the case of TPM, this applied to 13 patients, for
LEV to 44, PGB to seven, ZNS to ten, OXC(ER) to 13,
LCM to ten and ESL to just one patient.
By referring exclusively to the overall tolerability, LEV
emerged as best tolerated. The calculated RRs of ADR
occurrence per AED compared with LEV, which was set as
reference, ranged between 1.31 and 2.30, whereas again
just the total number of possibly related ADRs was taken
into account, not the clinical relevance of every single
ADR nor other tolerability influencing factors.
By means of the maximum applied dosages (Table 2), it
becomes apparent that in some cases the maximum applied
AED dosage exceeded the maximum permissible dosage
according to the particular SmPC [17–23]. For LCM, that
dosage was specified as 400 mg per day, for TPM and
ZNS, as 500 mg/day each, and for PGB, as 600 mg/day;
for ESL, OXC(ER) and LEV, the maximum approved
dosage was determined as 1200, 2400 and 3000 mg/day,
respectively. The proportion of off-label usage concerning
the maximum recommended daily dosage in the SmPC
varied between 6.4 and 64.7 % with regard to the total
number of patients the respective AED was part of therapy.
For further differentiation, the corresponding data of every
single AED, with and without ADR, is summarized in
Table 3. Comparing the calculated RR for each AED used
off-label to its application as recommended by the SmPC
revealed no relevant risk change. Though, the number of
patients for these evaluations was small.
Concerning the documented ADRs, the most common
were related to electrolyte imbalance, e.g., low sodium
(n = 79, 14.1 %) and potassium (n = 25, 4.4 %) levels,
the central nervous system, including dizziness (n = 61,
10.9 %), disturbed vision (n = 47, 8.4 %), fatigue
(n = 40, 7.1 %), nystagmus (n = 36, 6.4 %) and ataxia
(n = 29, 5.2 %), or cognitive deficits, especially distur-
bance of speech (n = 37, 6.6 %), memory impairment
(n = 36, 6.4 %) and mental slowing (n = 32, 5.7 %). In 24
patients (4.3 %), the observed ADRs were considered as
severe, rare, very distinctive or currently unknown and
Table 2 Patients without and
with at least possibly related
ADRs, stratified by the
respective AEDs, including
details of particular daily
dosages
N Totala (%) RRb CI Daily dosage (mg)
Mean Median SD Min. Max.
LEV
Without ADR 203 55.3 [1.00] 2596 3000 1107 250 6000
With possible ADR 120 32.7 2465 2500 1096 250 7000
PGB
Without ADR 26 42.6 1.31 0.89–1.93 487 600 187 75 750
With possible ADR 28 45.9 321 275 194 75 750
ZNS
Without ADR 26 38.2 1.40 0.98–2.02 256 250 164 50 600
With possible ADR 32 47.1 338 300 148 100 600
OXC(ER)
Without ADR 73 39.9 1.57 1.26–1.95 1715 1800 677 450 3850
With possible ADR 97 53.0 1646 1800 530 450 3000
LCM
Without ADR 37 36.3 1.63 1.24–2.13 326 350 144 50 600
With possible ADR 55 53.9 269 250 139 50 600
TPM
Without ADR 31 28.4 1.97 1.56–2.47 223 150 203 25 800
With possible ADR 65 59.6 213 200 119 50 500
ESL
Without ADR 2 11.8 2.30 1.75–3.02 1800 1800 849 1200 2400
With possible ADR 14 82.4 1514 1600 501 800 2400
AED antiepileptic drug, ADR adverse drug reaction, CI confidence interval, ESL eslicarbazepine, LCM
lacosamide, LEV levetiracetam, OXC(ER) oxcarbazepine extended-release formulation, PGB pregabalin,
RR relative risk for the occurrence of possibly related ADRs compared with the occurrence of these under
levetiracetam, SD standard deviation, TPM topiramate, ZNS zonisamide
a For calculation, the total number of documented cases per AED was used; the missing percentage up to
100 % fall upon ADRs assessed as unlikely, conditional or not causally linked to the particular AED
b For calculation of RR, patients taking both of the specifically compared AEDs were excluded
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therefore reported via the SRS to the responsible regulatory
authority. Among these reports were one case of an
arrhythmia absoluta under the combination of LCM and
LEV as a potentially life-threatening ADR, three of suici-
dal ideation (two under LEV, one under the combination of
OXC(ER)/LCM), three of myoklonia [two under
OXC(ER), one under LEV], two of peripheral edema under
OXC(ER), one of paresthesia under LEV, one of anorexia
under TPM and one case of anxiety under LEV.
For comparing the frequency of occurrence of particular
ADRs in relation to the information mentioned in the
SmPC, the incidence of the ADR was calculated for each
AED separately. The detailed results are shown in Table 4.
Although, SmPC data express a very rough classification
for ADR frequency by using categories differing by one
power of ten only, e.g., C0.1 % for an uncommon
and C10 % for a very common occurrence, for some reg-
istered ADRs probable underestimation was assumed. This,
for example, was apparent in the case of cognitive
impairment related to TPM and electrolyte imbalance
concerning potassium under therapy with an carbonic
anhydrase (CA) inhibitor (i.e., TPM, ZNS) or sodium level
by application of dibenzazepine anticonvulsants (i.e.,
OXC, ESL).
Table 3 Patients under off-
label use concerning dose,
without and with at least
possibly related ADRs, stratified
by the respective AEDs,
including details of particular
daily dosages
N Totala (%) RR CI Daily dosage (mg)
Mean Median SD Min. Max.
TPM
Off-label use 7 6.4
Without ADR 4 3.7 0.49 0.16–1.54 638 600 111 550 800
With possible ADR 2 1.8 650 650 71 600 700
LCM
Off-label use 18 17.6
Without ADR 8 7.8 0.84 0.50–1.40 513 500 58 450 600
With possible ADR 8 7.8 500 500 53 450 600
LEV
Off-label use 91 24.8
Without ADR 50 13.6 0.95 0.68–1.33 3945 4000 408 3500 6000
With possible ADR 27 7.4 4102 4000 701 3500 7000
PGB
Off-label use 6 9.8
Without ADR 3 4.9 0.96 0.42–2.24 725 750 43 675 750
With possible ADR 3 4.9 708 700 38 675 750
OXC(ER)
Off-label use 20 10.9
Without ADR 8 4.4 1.02 0.68–1.52 2994 3000 401 2550 3850
With possible ADR 11 6.0 2832 2700 316 2500 3600
ESL
Off-label use 11 64.7
Without ADR 1 5.9 1.03 0.78–1.36 2400 2400 2400 2400
With possible ADR 9 52.9 1822 1600 353 1600 2400
ZNS
Off-label use 7 10.3
Without ADR 2 2.9 1.21 0.66–2.23 600 600 0 600 600
With possible ADR 4 5.9 588 600 25 550 600
AED antiepileptic drug, ADR adverse drug reaction, CI confidence interval, ESL eslicarbazepine, LCM
lacosamide, LEV levetiracetam, OXC(ER) oxcarbazepine extended-release formulation, PGB pregabalin,
RR relative risk for the occurrence of possibly related ADRs comparing off-label use concerning dose to the
particular applications of the same drug used on-label, i.e., according to the recommended dosage by the
Summary of Product Characteristics, SD standard deviation, TPM topiramate, ZNS zonisamide
a For calculation, the total number of documented cases per AED was used
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Table 4 Incidence rates of all ADRs, assessed as at least possibly related to the antiepileptic drug, compared with corresponding frequency data
by the SmPC (nonexhaustive list; occurred ADRs mentioned only)
TPM LEV PGB ZNS OXC(ER) LCM ESL
Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC
Metabolism and nutrition disorders
Weight gain
N 3 7 2
% C1 0.8 C0.1 11.3 C1 N/A 1.1 N/A N/A N/A
Weight loss
N 9 2 3
% 8.2 C10 0.5 C0.1 C0.1 4.5 C1 N/A N/A C0.1
Decreased appetite/anorexia
N 5 5 3
% 4.5 C1 1.4 C1 N/A 4.5 C1 N/A N/A C1
Hypokalemia
N 11 3 9 1 3 1
% 10.1 C0.1 0.8 N/A C0.1 13.2 C0.1 0.6 N/A 2.9 N/A 5.9 N/A
Hyponatremia
N 3 1 67 3 10
% N/A 0.8 C0.01 1.6 N/A N/A 37.0 C1 2.9 N/A 58.8 C1
Psychiatric disorders
Sleep disturbance/insomnia
N 2 1 1 1
% C1 0.5 C1 1.6 C1 1.5 C1 N/A C1 5.9 C1
Nervousness/agitation
N 1 5 1 1 3 4 1
% 0.9 C1 1.4 C1 1.6 C0.1 1.5 C10 1.7 C1 3.9 C0.1 5.9 C0.1
Irritability
N 2 10 1
% 1.8 C1 2.7 C1 C1 C10 0.6 N/A C1 C0.1
Aggressive reaction
N 2 11 1 2 2 1
% 1.8 C1 3.0 C1 1.6 C0.1 3.0 C0.1 1.1 N/A 1.0 C0.1 N/A
Anxiety
N 4 1
% C1 1.1 C1 1.6 N/A C1 N/A N/A N/A
Listlessness/apathy
N 2 1 1
% C0.1 0.5 N/A 1.6 N/A N/A 0.6 C1 N/A C0.1
Mood swings/depressed mood
N 2 8 3 1 2
% 1.8 C10 2.2 C1 C0.1 4.5 C10 0.6 C1 1.9 C1 C0.1
Confusion
N 2 1
% C1 0.5 C0.1 C1 C10 0.6 C1 C1 C0.1
Suicidal ideation
N 1 4 1 1
% 0.9 C0.1 1.1 C1 N/A C0.1 0.6 N/A 1.0 C0.1 N/A
Nervous system disorders
Fatigue/tiredness
N 5 25 5 6 12 6 2
% 4.5 C10 6.8 C10 8.1 C10 9.0 C10 6.6 C10 5.8 C1 11.8 C10
Dizziness
N 5 23 7 5 24 25 5
% 4.5 C10 6.3 C1 11.3 C1 7.5 C10 13.3 C10 24.3 C10 29.4 C10
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Table 4 continued
TPM LEV PGB ZNS OXC(ER) LCM ESL
Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC
Nystagmus
N 4 10 5 2 13 19 4
% 3.6 C1 2.7 N/A 8.1 C0.1 3.0 C1 7.2 C1 18.4 C1 23.5 C0.1
Tremor
N 2 17 3 2 3 8 1
% 1.8 C1 4.6 C1 4.8 C1 3.0 C1 1.7 C1 7.8 C1 5.9 C1
Balance disorder/ataxia
N 3 10 2 2 12 11 2
% 2.7 C1 2.7 C1 3.2 C1 3.0 C10 6.6 C1 10.7 C1 11.8 C1
Disturbance in concentration/attention
N 16 3 2 2 1
% 14.7 C1 0.8 C0.1 C1 3.0 C1 1.1 C1 1.0 C1 C1
Memory impairment
N 25 11 2 6 3 2
% 22.9 C1 3.0 C0.1 3.2 C1 9.0 C10 1.7 C1 1.9 C1 C0.1
Disturbance of speech
N 31 4 3 4 2
% 28.4 C1 1.1 N/A C0.1 4.4 C1 2.2 N/A 1.9 C1 C0.1
Mental slowing/bradyphrenia
N 17 10 1 8 4 4
% 15.6 C1 2.7 N/A 1.6 C0.1 11.9 C1 2.2 N/A 3.9 C1 N/A
Headache
N 1 6 1 7 4 1
% 0.9 N/A 1.6 C10 1.6 C10 N/A 3.9 C10 3.9 C10 5.9 C1
Dysgeusia
N 1 1
% C1 0.3 N/A 1.6 C0.1 N/A N/A N/A N/A
Paresthesia
N 3 2
% 2.7 C10 0.5 N/A C1 C1 N/A C1 C0.1
Eye disorders
Blurred vision/diplopia
N 6 13 5 5 23 17 4
% 5.5 C1 3.5 C0.1 8.1 C1 7.5 C10 12.6 C10 16.5 C10 23.5 C1
Ear and labyrinth disorders
Tinnitus
N 1 1
% 0.9 C1 0.3 N/A N/A N/A N/A C1 C0.1
Gastro-intestinal disorders
Nausea/vomiting
N 3 4 1 13 15 2
% 2.7 C10 1.1 C1 1.6 C1 C1 7.2 C10 14.6 C10 11.8 C1
Diarrhea
N 1 1 1
% 0.9 C10 0.3 C1 C1 C1 C1 1.0 C1 C1
Obstipation
N 1 1 2 4 2
% 0.9 C1 N/A 1.6 C1 3.0 C1 2.2 C1 1.9 C1 C0.1
Flatulence
N 1 4
% C0.1 N/A C1 N/A 0.6 N/A 3.9 C1 C0.1
216 A. Hilgers, M. Schaefer
4 Discussion
4.1 AED Usage and ADR Incidence
Of the various AEDs of interest in this survey, OXC(ER)
and LEV were most frequently used. To our knowledge, no
study has so far investigated this selection of newer AEDs,
but there are three different papers reporting on the nation-
wide prescription patterns of AEDs in Italy (data included
until 2007), Norway (until 2009) and Germany (until 2010)
[13, 29, 30]. Extracting the data related to the AEDs
focused on in this survey also reveals the tendency towards
LEV being the most frequently used, followed by
OXC(ER), TPM, ZNS and PGB. LCM and ESL were the
most recently approved AEDs, which is why no reliable
data were available.
With regard to every first documented observation per
patient in this evaluation, almost 90 % were on polyther-
apy. Compared with the studies of Canevini et al. and
Malerba et al. in which 22.5 and 21 %, respectively, of
drug refractory patients were being managed on a single
AED [30, 31], a proportion of 10.1 % is small. However, in
our survey only patients recently admitted to in-house
treatment were included, for whom, other than severe
epilepsy, the need for a complex therapy management,
including administration of antiepileptic medication for
acute use and the change in therapy by gradual cross-over
of AEDs, can be assumed. By considering the calculated
mean data for the length of stay, number of concomitant
AEDs and AED load, defined as the sum of DDDs
(Table 1), this assumption can be substantiated.
It is still a matter of debate if antiepileptic polymedi-
cation compared with monotherapy is generally associated
with more frequent ADRs. The correlation between AED
toxicity and total drug load rather than the number of
concomitant AEDs is also still under discussion [31–34]. In
this survey, both factors were significantly associated with
a more frequent occurrence of ADRs, whilst also both were
strongly correlated with each other. However, in view of
the numerical extent of association, the total number of
AEDs seemed to be of greater impact. The reasons for this
can be manifold, including the absence of a rigid dosing
scheme, a gradual cross-over of AEDs, and the value of
DDD as an imperfect measure of drug exposure itself [15,
31, 35]. Testing for serum concentration-dependent toler-
ability was also considered for this survey, but ultimately
rejected as therapeutic drug monitoring of the newer AEDs
often was applied in selected cases only [36] and, therefore,
corresponding serum concentrations were not available in
every documented data set.
Table 4 continued
TPM LEV PGB ZNS OXC(ER) LCM ESL
Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC Obs. SmPC
Hepatobiliary disorders
Increase in liver enzymes
N 6 1 2 6 2 2
% C0.1 1.6 C0.1 1.6 C0.1 3.0 C1 3.3 C0.1 1.9 C0.1 11.8 C0.1
Skin and subcutaneous tissue disorders
Hypersensitivity/pruritus
N 2 1 1
% C1 0.5 C0.01 C0.1 C1 0.6 C0.001 1.0 C1 C0.1
Alopecia
N 1 2 2 1
% 0.9 C1 0.5 C0.01 N/A C1 1.1 C1 1.0 N/A C0.1
Musculoskeletal disorders
Myoclonia
N 1 1 2
% C1 0.3 N/A C0.1 1.5 N/A 1.1 N/A C1 N/A
General disorders
Peripheral edema
N 4 2 1
% N/A N/A 6.5 C1 C1 1.1 N/A N/A 5.9 C0.1
Total
N 109 367 61 68 183 102 17
% 100 100 100 100 100 100 100
ADR adverse drug reaction, ESL eslicarbazepine, LCM lacosamide, LEV levetiracetam, N/A not available, Obs. observed, OXC(ER) oxcarbazepine
extended-release formulation, PGB pregabalin, SmPC Summary of Product Characteristics, TPM topiramate, ZNS zonisamide
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The overall incidence of ADRs was calculated as
56.6 %, based on 318 patients for whom adverse reactions
were documented. With regard to the method of assessment
and the investigated patient population, this result corre-
sponds well with that of other studies. Canevini et al., who
also analyzed patients with drug-resistant epilepsy at ter-
tiary referral centers, identified ADRs in 36.5 % of
patients, based on spontaneous reporting, compared with
95.5 % when a validated screening questionnaire was used
[31]; similar results were summarized in a review of Per-
ucca and Gilliam [37]. Considering that the detection of
ADRs in clinical routine is derived from spontaneous
reporting complemented by medical examination and lab
diagnostics, and in view of the findings by Baker et al.,
which indicate a prevalence underestimation of ADRs
when based on spontaneous reporting versus overestima-
tion when using checklists, the extent of prevalence in this
survey can be considered plausible for a real-life hospital
setting [38].
Concerning the overall tolerability, LEV emerged as best
tolerated, which, similarly, was reported by Cramer et al.
[28]. This may be a reason for it being first recommended
and therefore frequently used, as also indicated by the high
number of patients under LEV in this survey. The calculated
RRs of ADR occurrence for each AED compared with LEV
varied between 1.31 and 2.30. But these values should be
treated with caution; for the evaluation, only the total
number of possibly related ADRs was taken into account,
and not the type nor the clinical relevance of the ADR, nor
other tolerability influencing factors. The impact of associ-
ated ADRs can be very different, which is why by using this
kind of RR calculation only the overall tolerability can be
estimated and has to be reviewed in every single case [31,
37]. Furthermore, all patients were preselected due to real-
life conditions, and the total number of patients treated with
particular AEDs varied widely, which in itself may have had
an impact on the estimated RR.
An interesting finding of this survey was the rather high
proportion of off-label use concerning maximum recom-
mended daily dosage (Table 3). So far, there are not many
studies investigating off-label use by dose in drug resistant
epilepsy. One study by Franco et al. focused on this
question by means of a diagram, showing proportions of
off-label use of between 0 and 25 % [39]. The values in our
survey ranged from 6.4 % for TPM up to 64.7 % for ESL.
By comparing the calculated RR for each AED used off-
label to its application as recommended by the SmPC, no
considerable change of ADR occurrence was seen. How-
ever, the documented extent of off-label use showed an
obvious relevance for clinical practice, indicating the need
of further investigations on potential risks and benefits to
alleviate physicians’ and patients’ uncertainty whilst using
a drug out of its specification [39].
As already mentioned, antiepileptic therapy often means
a balancing act between optimizing therapeutic outcome
and running the risk of ADRs [6–8, 14, 15, 31, 37, 40–42].
It is therefore important to be aware of the side effect
profiles of every considered AED in order to choose the
best therapy option for every patient. The comparison of
incidences of ADRs with possible causality in relation to
the information mentioned in the SmPC, which, to our
knowledge, was first performed in this survey, is very
valuable to provide a supplementary assessment of partic-
ular risk. Even though, SmPC data present a very rough
estimate for ADR frequency by using categories differing
by one power of ten only, e.g., C0.1 % for an uncommon
and C10 % for a very common occurrence, for some of the
documented ADRs, a probable underestimation was
determined. For example, in the case of cognitive impair-
ment related to TPM or electrolyte imbalance under ther-
apy with a CA inhibitor (i.e., TPM, ZNS) or dibenzazepine
anticonvulsants (i.e., OXC, ESL), the discrepancy was
particularly apparent.
It is a well known fact that the detection of specific
ADRs can be influenced by physicians’ expectations as to
the likelihood of occurrence [8, 31]. Therefore, it cannot be
excluded that applied targeted testing, such as close control
of lab values, will cause a detection bias.
TPM and ZNS are known as inhibitors of CA, which has
a considerable share in regulating the acid–base balance
and therefore influences the electrolyte status. In this sur-
vey, low potassium levels (\3.6 mEq/L) were assessed for
11 and nine patients on TPM and ZNS (10.1 and 13.2 %),
respectively, although the SmPC of both drugs mention this
to be an uncommon occurrence (C0.1 and\1 %) [17, 20].
A similar result for TPM was found in a systematic review
by Dell’Orto et al., indicating hypokalemia as concomitant
with metabolic acidosis for 10 % of the cases [43]. To our
knowledge, there are no comparable investigations refer-
ring to potassium levels under ZNS treatment, but a study
by Mirza et al. indicated similar inhibitor potency to CA
isoforms by TPM and ZNS, both inducing renal tubular
acidosis [44]. Therefore, it seems plausible to detect an also
increased frequency of hypokalemia under ZNS. Further
investigations are definitely necessary to verify these
results, but until then, the potential risk of CA inhibitors
should be considered, particularly in patients with co-
morbidity or co-medication influencing electrolyte balance.
The same applies to treatment regimes with OXC(ER)
or ESL, for which a higher incidence of hyponatremia,
compared with SmPC data, was documented [21, 23]. As
possible reasons, the previously mentioned detection bias
or other influencing factors, like vomiting, diuretic or
psychotropic medication, heart or kidney insufficiency,
etc., should be also taken into account. Furthermore, the
varying reference values applied for the definition of
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hyponatremia in different studies (here\135 mEq/L) and
the highly selected patient population in this survey should
be considered. Apart from this, there are many studies
mentioning the frequency of decreased sodium serum
levels in about 10–30 % of the patients under OXC treat-
ment, which in turn substantiates an assumed higher risk
[45–50]. At the time of approval, ESL was promoted as
bearing a lower hyponatremia risk compared with OXC.
However, studies by Ley et al. and Gupta et al. could not
substantiate this claim [51, 52]. In our survey, almost all
patients with ESL stopped OXC(ER) because of decreased
sodium levels prior. Therefore, the previous experience of
hyponatremia could be an explanation for the high inci-
dence even under ESL. But interesting in this context, data
concerning hyponatremia mentioned in the SmPC have,
since approval, been adjusted to a common frequency (C1
and\10 %), therefore, indicating the same risk as for
OXC(ER), by now [23, 53].
With regard to cognitive impairment (e.g., psychomotor
slowing, difficulty with concentration/attention, difficulty
with memory, speech or language problems, particularly
word-finding difficulties), this is a well described problem
in patients on TPM [42, 54–59]. Being aware of that,
neuropsychological testing and retesting (investigating
cognitive processing, memory, language) are more often
applied in conjunction with TPM therapy, as for example,
recommended by Lee et al. [60]. This may have induced an
overestimation of the particular risk in this survey, since
cognitive impairment is also known to be influenced by
seizure frequency and an increased number and dosage of
AEDs [56]. However, a review by Mula, investigating the
evidence of cognitive impairment under TPM, established
that approximately 10 % of the patients experienced cog-
nitive problems [58]. Of these, as also confirmed in our
survey, speech problems mainly concerning verbal fluency
were the most prominent [58, 61], a fact, which should be
considered in individual treatment plans, especially for
patients actively working or studying.
In conclusion, the results of this survey show that a sys-
tematic evaluation of inpatient data allows for even more
information to be gained than could be extracted from clin-
ical trials or SRS. Therefore, this kind of surveillance can
provide a decisive contribution to future adjustments of risk
data, applied to align approval data with real-life experience,
which is an ongoing process, as the comparison of SmPC
data from 2011 and 2015 reflects [17–23, 53, 62–67].
4.2 Methodological Considerations
Within this project, data were collected weekly by a phar-
macist as part of the Consultants’ ward rounds. It cannot be
excluded that short-stay patients were missed, which could
have biased the selection of patients towards more complex
therapies. For this reason and to avoid time-consuming re-
documentation of paper notes, the implementation of elec-
tronic patient records is to be recommended. For ADR
documentation, no standardized questionnaire was used in
this survey, which may have underrated some ADR inci-
dences. However, by using thismethod, theADR assessment
remained as close to clinical routine as possible, and is
therefore assumed to reflect the problems and concerns of
practical relevance. A challenge, which is inherent in the
system, is the real-life data assessment itself. Influencing
factors, such as dose adjustment, change of therapy regime,
co-morbidity or concomitant drug use, etc., do not follow a
precise study plan under these conditions. Thus, the causality
assessment and calculation of RRs concerning ADR are only
methodical approaches to deal with these data, and the cor-
responding results should be judged in context and treated
with caution. Due to this, not every pointed question of sci-
entific interest can be proven or rejected. Moreover, neither
the applied method nor all of the results can be translated to
patients treated at primary care level or those being well
controlled concerning seizure frequency and tolerability. But
by this approach, treatment issues relevant to all patients can
be identified and used as guidance for further investigation.
The major advantage of this method lies in the
prospectively orientated full assessment of patients. It
provides reliable application data, and the rather long-term
observation period, the accumulation of medical informa-
tion and the opportunity of monitoring progress, encourage
the evaluation of causal relations between ADRs and sus-
pected drugs.
5 Conclusion
For patients depending on lifelong treatment, optimized
therapies adapted to individual needs are of great impor-
tance. For this purpose, established expertise in the
advantages and disadvantages of each drug is indispens-
able. It has been shown that during inpatient treatment,
valuable data are generated. A systematic assessment and
continuous evaluation of these data can constitute a chance
for perpetual risk and treatment evaluation under real-life
conditions and therefore support individualized therapy
management. Accordingly, even if this approach may need
more methodological reasoning, it would certainly provide
a new quality of drug surveillance.
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